АЛЛОГЕННАЯ ТРАНСПЛАНТАЦИЯ ГЕМОПОЭТИЧЕСКИХ СТВОЛОВЫХ КЛЕТОК У ДЕТЕЙ: НАСТОЯЩЕЕ, ПРОБЛЕМЫ, ПЕРСПЕКТИВЫ

Трансплантация гемопоэтических стволовых клеток (ТГСК) является ведущим методом лечения злокачественных заболеваний системы крови и наследственных заболеваний, а также ряда солидных опухолей у детей, подразделяется на аутологичную (ауто-ТГСК) и аллогенную (алло-ТГСК) трансплантации. Проведение ТГСК осуществляется с учетом показаний, наличия донора – родственного, неродственного, гаплоидентичного, с применением режимов кондиционирования различной интенсивности (миело аблативные, режимы кондиционирования сниженной интенсивности доз, немиелоаблативные), профилактики реакции «трансплантат против хозяина», которая является ведущим осложнением. Наряду с цитостатическим воздействием при выполнении алло-ТГСК осуществляется иммуноадоптивный эффект – «трансплантат против лейкоза».

1. Passweg J. R., Baldomero H., Bader P. et al.; European Society for Blood and Marrow Transplantation (EBMT). Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants. Bone Marrow Transplant 2015;50(4):476–82.

2. Chang Y.-J., Huang X.-J. Use of G-CSF-stimulated marrow in allogeneic hematopoietic stem cell transplantation settings: a comprehensive review. Clin Transplant 2011;25(1):13–23.

3. Rutella S., Zavala F., Danese S. et al. Granulocyte colony-stimulating factor: a novel mediator of T-cell tolerance. J Immunol 2005;175(11):7085–91.

4. Maziarz R. T., Nademanee A. P., Micallef I. N. et al. Plerixafor plus granulocyte colony-stimulating factor improves the mobilization of hematopoietic stem cells in patients with non-Hodgkin lymphoma and low circulating peripheral blood CD34+ cells. Biol Blood Marrow Transplant 2013;19(4):670–5.

5. Halter J., Kodera Y., Urbano Ispizua A. et al. Severe events in donors after allogeneic hematopoietic stem cell donation. Haematologica 2009;94(1):95–101.

6. Purtill D., Smith K., Devlin S. et al. Dominant unit CD34+ cell dose predicts engraftment after double-unit cord blood transplantation and is influenced by bank practice. Blood 2014;124(19):2905–12.

7. Kwon M., Bautista G., Balsalobre P. et al. Haplo-cord transplantation using CD34+ cells from a third-party donor to speed engraftment in high-risk patients with hematologic disorders. Biol Blood Marrow Transplant 2014;20(12):2015–22.

8. Ratajczak M., Suszynska M., Pedziwiatr D. et al. Umbilical cord blood-derived very small embryonic like stem cells (VSELs) as a source of pluripotent stem cells for regenerative medicine. Pediatr Endocrinol Rev 2012;9(3):639–43.

9. Зубаровская Л. С., Фрегатова Л. М., Афанасьев Б. В. Трансплантация гемопоэтических стволовых клеток. В кн.: Клиническая онкогематология. Под ред. М. А. Волковой. М.: Медицина, 2007. С. 912– 962. [Zubarovskaya L. S., Fregatova L. M., Afanasiev B. V. Hematopoietic stem cell transplantation. In: Clinical oncohematology. M. A. Volkova (ed.). M.: Medicine, 2007. Pp. 912–962. (In Russ.)].

10. Welte K., Foeken L., Gluckman E. et al. International exchange of cord blood units: The registry aspects. Bone Marrow Transplant 2010;45(5):825–31.

11. Kekre N., Antin J. Hematopoietic stem cell transplantation donor sources in the 21st century: choosing the ideal donor when a perfect match does not exist. Blood 2014;124(3):334–43.

12. Кузьмич Е. В., Алянский А. Л., Иванова Н. Е. и др. Анализ результатов аллогенной трансплантации гемопоэтических стволовых клеток в зависимости от степени HLA-подбора пациента и не-родственного донора. Онкогематология 2014;3:25–31. [Kuzmich Ye. V., Alyanskiy A. L., Ivanova N. Ye. Analysis of the results of allogeneic hematopoietic stem cell trans-plan tation depending on HLA matchingof the unrelated donor/recipient pair. Onkogematologiya = Oncohematology 2014;3:25–31. (In Russ.)].

13. Afanasyev B. Conditioning regimens for allogeneic (allo)-SCT. EBMT-EHA Hematology Tutorial on Bone Marrow Transplantation 2013. Pp. 9–13.

14. Bunin N., Aplenc R., Kamani N. et al. Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: a Pediatric Blood and Marrow Transplant Consortium study. Bone Marrow Transplant 2003;32(6):543–8.

15. Champlin R., Knouri I., Shimoni A. et al. Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol 2000;111(1):18–29.

16. Giralt S., Ballen K., Rizzo D. et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2009;15(3):367–9.

17. Sureda A., Bader P., Cesaro S. et al. Indication for allo- and auto-HSCT for hematological diseases, solid tumors and immune disorders: current practice in Europe, 2015. Bone Marrow Transplant 2015. [Epub ahead of print].

18. Vora A., Goulden N., Wade R. et al. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. Lancet Oncol 2013;14(3):199–220.

19. Creutzig U., Heuvel-Elbrink M., Gibson B. et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood 2012;120(16):3187–205.

20. Moricke A., Zimmerman M., Reiter A. et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia 2010;24(2):265–84.

21. Румянцева Ю. В., Карачунский А. И., Румянцев А. Г. Оптимизация терапии острого лимфобластного лейкоза у детей в России. Педиатрия 2009;84(4):19–27. [Rumyantseva Yu. V., Karachunsky A. I., Rumyantsev A. G. Optimization of the treatment of acute lymphoblastic leukemia in children in Russia. Pediatriya = Pediatrics 2009;84(4):19–27. (In Russ.)].

22. Peters C., Schrappe M., von Stackelberg A. et al. Stem cell transplantation in children with acute lymphoblastic leukemia: a prospective international multicenter trial comparing sibling donors with matched unrelated donors – The ALL-SCT-BFM-2003 trial. J Clin Oncol 2015;23(11):1265–74.

23. Moorman A., Enshaei A., Schwab C. et al. A novel integrated cytogenetic and genomic classification refines risk stratification in pediatric acute lymphoblastic leukemia. Blood 2014;124(9):1434–44.

24. Locatelli F., Schrappe M., Bernando M., Rutella S. How I treat relapsed childhood acute lymphoblastic leukemia. Blood 2012;120(14):2807–16.

25. Borgmann A., Stackelberg A., Hartmann R. et al. Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission: a matched-pair analysis. Blood 2003;101(10):3835–9.

26. Pui C., Carroll W., Meshinchi S., Arceci R. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol 2011;29(5):551–65.

27. Eapen M., Raetz E., Zhang M. et al. Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission:

28. a collaborative study of the Children,s Oncology Group and the Center for International Blood and Marrow Transplant Research. Blood 2006;107(12):4961–7.

29. Семенова Е. В. Роль трансплантации гемопоэтических стволовых клеток в те-рапии острого лимфобластного лейкоза у детей и подростков группы высокого риска. Автореф. дис. ... д-ра мед. наук. СПб., 2014. [Semenova E. V. The role of hematopoietic stem cell transplantation in the treatment of acute lymphoblastic leukemia in children and adolescents at high risk. Dissert. D. Sci. Saint-Petersburg, 2014. (In Russ.)].

30. Verneris M. R., Eapen M., Duerst R. et al. Reduced-intensity conditioning regimens

31. for allogeneic transplantation in children with acute lymphoblastic leukemia. Biol Blood Marrow Transplant 2010;16(9):1237–44.

32. Stackelberg A., Völzke E., Kühl J. Outcome of children and adolescents with relapsed acute lymphoblastic leukaemia and non-response to salvage protocol therapy: a retrospective analysis of the ALL-REZ BFM Study Group. Eur J Cancer 2011;47(1):90–7.

33. Paina O., Stancheva N., Semenova E. et al. Haploidentical hematopoietic stem cell transplantation in children and adolescents with acute leukemia in progressive disease: MAC vs RIC, PTCY vs conventional prophylaxis of aGVHD, T-cell depleted vs T-cell replete haplo-grafts. Bone Marrow Transplant 2015;50(Suppl 1):25S.

34. Pigazzi M., Manara E., Buldini B. et al. Minimal residual disease monitored after induction therapy by RQ-PCR can contribute to tailor treatment of patients with t(8;21) RUNX1-RUNX1T1 rearrangement. Hematologica 2015;100(3):e99–101.

35. Kaspers G., Zwaan C. Pediatric acute myeloid leukemia: towards high-quality cure of all patients. Haematologica 2007;92(11):1519–32.

36. Creitzig U., Kaspers G. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2004;22(16):3432–3.

37. Kaspers G. How I treat paediatric relapsed acute myeloid leukaemia. Br J Haematol 2014;166(5):636–45.

38. Pession A., Masetti R., Rizzari C. et al. Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia. Blood 2013;122(2):170–8.

39. Bunin N. J., Davies S. M., Aplenc R. et al. Unrelated donor bone marrow transplantation for children with acute myeloid leukemia beyond first remission or refractory to chemotherapy. J Clin Oncol 2008;26(26):4326–32.

40. Locatelli F., Masetti R., Rondelli R. et al. Outcome of children with high-risk acute myeloid leukemia given autologous or allogeneic hematopoietic cell transplantation in the AIEOP AML-2002/01 study. Bone Marrow Transplant 2015;50(2):181–8.

41. Andolina J., Neudorf S., Corey S. How I treat childhood CML. Blood 2012;119(8):1821–30.

42. Holtan S., Pasquni M., Weisdorf D. Acute graft-versus-host disease: a bench-to-bedside update. Blood 2014;124(3):363–73.

43. Glucksberg H., Storb R., Fefer A. et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974;18(4):295–304.

44. Rowlings P., Przepiorka D., Klein J. et al. IBMTR Severity Index for grading acute graft-versus host disease: retrospective comparison with Glucksberg grade. Br J Haematol 1997;97(4):855–64.

45. Levine J., Harris A., Taylor A. et al. A biomarker-based grading system at onset of GvHD predicts NRM better than the modified glucksberg grading system. Blood 2013;122(21).

46. Morichima Y., Kashiwase K., Matsuo K. et al. Biological significance of HLA locus matching in unrelated donor bone marrow transplantation. Blood 2015;125(7):1189–97.

47. Luznik L., Jones R. J., Fuchs E. J. High-dose cyclophosphamide for graft-versus-host disease prevention. Curr Opin Hematol 2010;17(6):493–9.

48. Ruutu T., Gratwohl A., de Witte T. et al. Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations foe standardized practice. Bone Marrow Transplant 2013;49(2):168–73.

49. Ball L. M., Bernardo M. E., Roelofs H. et al. Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III–IV acute graft-versus-host disease. Br J Haematol 2013;163(4):501–9.

50. Shulman H., Sullivan K., Weiden P. et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980;69(2):204–17.

51. Socie G., Ritz J. Current issues in chronic graft-versus-host disease. Blood 2014;124(3):374–84.

52. Lee S. J., Wolff D., Kitko C. Measuring Therapeutic Response in Chronic Graft-versus-Host Disease. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2014 Response Criteria Working Group Report. Biol Blood Marrow Transplant 2015;21(6):984–99.